This paper reviews the behaviour of intraocular pressure (lOP) in glaucomatous eyes treated with metipranolol with and without drug-induced adverse reactions (ADRs). Two hundred and forty seven patients with open angle glaucoma who were receiving the three different strengths of metipranolol (0.1 %, 0.3 %, and 0.6 % ) in our Department and the 7 patients who participated in the metipranolol rechallenge trial were included in this study.
Elevation of intraocular pressure (lOP) is a well recog nised complication of intraocular inflammation but its prevalence in the various inflammatory conditions as reported by several authors vary markedly. For example, the incidence of secondary glaucoma in patients with acute uveitis is quoted between 12%1 and 15%,2 but in Fuch's Heterochromic Cyclitis estimates vary from 9%3 to 59%. 4 There is however, very little in the literature on the prevalence of secondary elevation of lOP in glaucomatous eyes with ocular inflammation.
We described in a previous paper5 the adverse reactions associated with the use of topical metipranolol in glauco matous eyes i.e. granulomatous anterior uveitis, marginal keratitis, blepharoconjunctivitis and periorbital dermat itis. Some of these glaucomatous eyes with controlled lOP exhibited secondary elevation in lOP with the develop-ment of the metipranolol-induced adverse drug reactions (ADRs) which was not unexpected in those eyes with intraocular inflammation but was inexplicable in eyes with external ocular inflammation and those without any clinical signs of inflammation.
In this paper we continue our investigation of metipra nolo I-induced ADRs. We studied the behaviour of lOP in glaucomatous eyes with metipranolol-induced ADRs and also in those metipranolol treated eyes without clinical signs of ADRs.
PATIENTS AND METHODS
We reviewed retrospectively the case-notes of all patients treated with metipranolol in our department and examined those patients who responded to an invitation to attend special clinics as described in the previous paper. 5 The behaviour of the lOP in the eyes of those patients entered into the rechallenge study were also analysed. 6 In the light of the preliminary results of the above two studies we further reviewed the behaviour of lOP in all glaucomatous eyes who had been controlled with metipra nolol 0.6% only.
RESULTS
Two hundred and forty seven glaucoma patients in our department were treated with guttae metipranolol: 109 with metipranolol 0.6%, 103 with metipranolol 0.3% and 35 with metipranolol 0.1 % Seven patients completed the metipranolol rechallenge study.
From case-notes and clinical reviews we found 29 patients (52 eyes) with metipranolol-induced ADRs: granulomatous anterior uveitis (15 patients, 25 eyes); ble pharoconjunctivitis (11 patients, 21 eyes); combined granulomatous anterior uveitis and blepharoconjunctivitis (2 patients, 4 eyes); periorbital dermatitis (1 patient, 2 eyes); and marginal keratitis (1 patient, 2 eyes).
There was a total of 78 different recorded episodes of ADRs suffered by the 52 eyes of the 29 patients. In 45 epi sodes (57.6%) there was a significant elevation in lOP (;:, 5 mm Hg) associated with the ADR. The distribution of the patients, eyes and episodes in which there was loss of IOP control is shown Table I . In 42 out of the 45 (93.3%) episodes of ADR with elevation of IOP the responsible drug was metipranolol 0.6% and in the remaining 3 episodes (6.7%) metipranolol 0.3% was implicated ( Table 11 ).
The 27 episodes (out of a total of 46 episodes) of granu lomatous anterior uveitis with loss of lOP control had a range of f:, lOP from 8 to 32 mm Hg with a mean f:, lOP of 16.7 mm Hg (SD 6.3). There were 11 episodes of ble pharoconjunctivitis with loss of lOP control (11 out of 20), range of f:, lOP 5-18 mm Hg and mean f:, lOP 10.3 mm Hg (SD 4.6) and 3 episodes of combined granuloma tous anterior uveitis and blepharoconjunctivitis with sig nificant elevation in lOP (3 out of 8), had a range f:, lOP 8-22 mm Hg and mean f:, lOP 11.6 mm Hg (Table III) .
Two metipranolol 0.3% treated eyes of the 7 patients in the rechallenge study showed an elevation of lOP within two weeks of the start of the study, 1 of them without any signs of ocular inflammation and a f:, lOP of 17 mm Hg. The other eye had granulomatous anterior uveitis, blepha roconjunctivitis, ectropion secondary to the skin changes and a f:, IOP 22 mm Hg.
The further review of patients and case-notes revealed 27 eyes of 14 p � tien�s on metipranolol 0.6% only with sig mficant elevatIOn m lOP (;:: 5 mm Hg) prior to the development of any recognisable clinical features of �DRs. Five of these eyes later developed metipranolol mduced granulomatous anterior uveitis within a few weeks. The other 22 eyes of 11 patients in this group were changed from metipranolol 0.6% to other anti-glaucoma Table II medications (timolol maleate 0.5%, 10 eyes; carteolol 2%, 8 eyes; levobunolol 0.5%, 2 eyes; pilocarpine 1 % 2 eyes) which controlled the lOP and were therefore not seen to develop any metipranolol-induced ADRs.
DISCUSSION
The incidence of secondary glaucoma in patients with acute uveitis in non-glaucomatous eyes in other studies varies between 12% (IOP>21 mm Hg on at least two occasions)l and 15% (IOP>25 mm Hg).2 Jones7 review of glaucoma in 103 patients with Fuch's Heterochromic Cyclitis showed an incidence of 26.2% but other investi gators have reported estimates which vary from 9%3 to 59%4 This paper reviews the secondary elevation in lOP seen in eyes with primary glaucoma treated by metripranolol with or without the various forms of metipranolol-induced ADRs. As far as could be determined from the case notes the . 52 eyes of the 29 patients who developed metiprano� lo�-mduced ADRs had controlled lOPs i e. <22 mm Hg pnor to the first documentation of an ADR. Where an eye suffered more than one episode of ADR (as there were a total of 78 episodes in this group) the lOP returned to within normal limits on the same anti-glaucoma treatment before the development of subsequent ADRs. In this group of glaucomatous eyes therefore, further elevation in lOP was only seen with an active ADR.
In this study, loss of IOP control or significant elevation in lOP is taken as an increase in lOP greater than 5 mm Hg.
The incidence of loss of lOP control was similar in the three sub-groups of ADRs: granulomatous anterior uveitis 59%, blepharoconjunctivitis 60% and granulomatous anterior uveitis and blepharoconjunctivitis combined 62.5%. In the sub-group with marginal keratitis the 2 eyes affected showed this phenomenon (100%) but the number is too small for any meaningful conclusion. The 2 glauco matous eyes with metipranolol-induced periorbital der matitis did not show any loss of lOP control.
Panek! listed several pathophysiological mechanisms for the elevation of lOP in eyes with uveitis: The five sub-groups of metipranolol-induced ADRs represent three different forms of ocular inflammation. The granulomatous anterior uveitis and the combined granulomatous anterior uveitis and blepharoconjunctivitis sub-groups both show signs of intraocular inflammation which can be associated with elevation in lOP in 12-15% of normal eyes,2,3 but in our study the prevalence was 59% and 62.5% respectively in the two sub-groups of glauco matous eyes with ADRs which is significantly higher. Kinshuck8 reported an elevation in lOP in 13 out of his 16 glaucomatous eyes (87%) with metipranolol-associated granulomatous anterior uveitis.
The two sub-groups of external ocular inflammation, i.e. blepharoconjunctivitis and marginal keratitis, are not often associated with secondary elevation in lOP unless the external inflammation is so severe as to be accom panied by decompensation of the blood-aqueous barrier. In this study the prevalence of secondary elevation in lOP was 60% and 100% respectively in the two sub-groups. We were unable to find any figures in the literature for the prevalence of secondary glaucoma in normal or glauco matous eyes with external ocular inflammation but the figures obtained in our study are considerably higher than would have been expected. The case of periocular der matitis represents inflammation of the adnexal structures and would not have been expected to demonstrate a change in lOP.
It is difficult to postulate a single mechanism of action for the elevation in lOP seen in the different forms of meti pranolol-induced inflammations without implicating the active drug, i.e. metipranolol. If this was the case, then, one would expect a number of eyes on metipranolol with loss of IOP control and no clinical signs of ADRs. Indeed, there were 27 eyes of 14 patients out of 109 patients receiving metipranolol 0.6% in which this was observed, 22 of these eyes had no sign of ADR when the metiprano-1 0 10.6% was changed to other ophthalmic topical medi cations because of loss of lOP control. However, there is a possibility that the loss of lOP control was due to pro-
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gression of the glaucoma and not related to the use of meti pranolol. The trend of elevation in lOP was not gradual as would be expected for worsening of glaucoma and also the fact that lOP control was achieved very quickly with a comparable or less efficacious anti-glaucoma therapy, both support the view that the loss of IOP control might be related to metipranolol. The lOPs in these eyes have remained within normal limits without additional anti glaucoma therapy for two years.
The mean elevation in lOP was highest in the uveitic sub-group ie 16.7 mm Hg. These eyes were managed in different ways but unfortunately the number of eyes in each treatment group is too small for any objective con clusions. All the eyes showed return of lOP to within normal range except in one eye which had pseudoexfoli ative glaucoma and finally required filtration surgery.
The exact mechanism of the secondary elevation ofIOP is unknown but probably associated with some changes in the trabecular meshwork caused by the active drug, meti pranolol, itself. There were no additional findings in the iridocorneal recess on gonioscopic examination. Also there were no significant differences in age, sex, time since glaucoma was first diagnosed, period on metiprano-1 0 1 , associated diseases or other medications which may indicate any predisposition for the decompensation of tra becular function with further reduction in outflow facility and consequently the loss of IOP control. The rather quick recovery of lOP control in these eyes, both those with and those without metipranolol-induced ADRs, when meti pranolol was discontinued suggest that the secondary ele vation in lOP was not due to progression of the disease. The behaviour of the lOP in these metipranolol treated eyes is not similar to that experienced with long term use of timolol (the 'long-term drift') which has been described by other authors.Y, !O Also, this phenomenon of loss ofIOP control has been observed after a very short period of meti pranolol treatment, for example, the 2 eyes in the rechal lenge study with marked elevation in lOP within two weeks of treatment with metipranolol 0.3% This evidence is against progression of the disease or loss of drug effi cacy as the cause of the secondary elevation in lOP in these metipranolol treated eyes.
In conclusion, this study reveals a high incidence of secondary elevation in lOP in glaucomatous eyes treated with metipranolol 0.3% and 0.6% The intraocular inflam matory ADRs associated with metipranolol could com promise further the reduced outflow facility of these glaucomatous eyes but this is not a plausible explanation for the loss of lOP control in all the different types of ADRs, and in particular, for those eyes without clinical signs or symptoms of ADRs. It is suggested that the active drug, metipranolol, is implicated directly in the pathophy siology of this secondary elevation in lOP.
